Strong Eczema Response to JAK Inhibitor
MedPage Today SAN DIEGO — Patients with moderate or severe atopic dermatitis (AD) had as much as 74% improvement in disease status with the oral Janus kinase (JAK) inhibitor upadacitinib, a randomized trial showed. After 16 weeks, patients randomized to one of … |